Genmab stocks have experienced considerable action recently, notably spurred by the company's acquisition of
Merus, a cancer-focused firm. This $8 billion deal alone has seen Genmab shares surge by 64%, following a May fair value alert. Several investment firms have consequently adjusted their rating on Genmab.
Truist Securities raised its stock price target to $49, while H.C. Wainwright increased its target first from $36 to $40 and once more to $46. Contrarily,
Bernstein reiterated a sell rating on Genmab. Nevertheless, definite demand for Genmab's products, such as Darzalex, is driving growth, with the company also broadening its late-stage pipeline. Yet, Genmab is experiencing some financial challenges despite strategic moves. The company saw a 21.9% leap in stock within a month following the Merus acquisition deal. However, there has been a 58.2% increase in short interest in Genmab. Despite this, shares have grown, Genmab earning a buy recommendation from
Guggenheim and H.C. Wainwright. The firm's future looks promising with
data-driven models highlighting long-term capital growth prospects.
Genmab Stocks News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 11 Oct 2025 09:20:05 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -5
